Loading...
Melanoma has a propensity to widely metastasize, and tumor vascularity is required for metastatic hematogenous spread of malignant cells. Thus, angiogenesis — the recruitment of endothelial cells to the tumor microenvironment for the development of new vasculature formation by the secretion of factors such as vascular endothelial growth factor (VEGF) — has been studied as a potential therapeutic target for patients with melanoma. However, using anti-angiogenesis agents such as bevacizumab, which targets VEGF, has not been shown to improve overall survival (OS) in melanoma patients, suggesting alternate targets may play a role in angiogenesis.
Now, investigators have analyzed data from the AVAST-M trial (Ann Oncol 2018; 29:18), in which 1343 …